$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
DBMR has added a new report titled Anti-Infective Drugs Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This research report is generated by thoroughly understanding
New filing by GLAXOSMITHKLINE LLC PAC (GSK PAC)
09:30pm, Wednesday, 17'th Nov 2021 The FEC
The GLAXOSMITHKLINE LLC PAC (GSK PAC) successfully filed their F3XN NOVEMBER MONTHLY with the coverage period of 10/01/2021 to 10/31/2021 and a confirmation ID of FEC-1548728 *********CommitteeId: C00199703 | FilingId: 1548728 | FormType: F3XN | CoverageFrom: 10/01/2021 | CoverageThrough: 10/31/2021 | ReportType: NOVEMBER MONTHLY*********
Paediatric Epilepsy Therapeutics Market Focusing on Current Trends, Leading with Top Key Players like Abbott., GlaxoSmithKline plc., Cephalon, Inc., Johnson & Johnson
05:25pm, Wednesday, 17'th Nov 2021 OpenPR
DBMR has added a new report titled Paediatric Epilepsy Therapeutics Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. The credible report comprises of the market
U.S. places a sizable order for GSK-Virs COVID-19 treatment
04:41pm, Wednesday, 17'th Nov 2021 Invezz
Britains GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th The number of doses of Sotrovimab [] The post U.S. places a sizable order for GSK-Virs COVID-19 treatment appeared first on Invezz .
GlaxoSmithKline goes ex-dividend tomorrow
03:12pm, Wednesday, 17'th Nov 2021 Seeking AlphaUS Government Agrees To Purchase GSK-Vir Biotech''s COVID-19 Antibody Doses Worth $1B
02:54pm, Wednesday, 17'th Nov 2021 Benzinga
The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc (NASDAQ: VIR ). GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally. The U.S. deliveries of sotrovimab are expected by … Full story available on Benzinga.com
Robitussin Teams Up with Tony Award-Winning Actress, Adrienne Warren, to Help Increase Access to the Performing Arts in Underserved Communities
02:07pm, Wednesday, 17'th Nov 2021 PR Newswire
WARREN, N.J., Nov. 17, 2021 /PRNewswire/ -- GSK Consumer Healthcare''s (LSE/NYSE: GSK) Robitussin brand today announced a partnership with the All Stars Project, Inc. to help provide access to performing arts education for youth in underserved communities. Robitussin believes that everyone
Stocks making the biggest moves premarket: Lowe''s, Target, GlaxoSmithKline and others
12:46pm, Wednesday, 17'th Nov 2021 CNBC
These are the stocks posting the largest moves before the bell.
Artificial Saliva Market Size 2021, Global Industry Analysis, Segments, Drivers and Trends to 2027|GlaxoSmithKline, Cipla Limited, Fresenius Kabi
12:05pm, Wednesday, 17'th Nov 2021 OpenPR
The global Artificial Saliva market will grow at a CAGR of 8.42% from 2021 to 2027. Artificial saliva is used in the treatment of dry mouth. The rising incidents of cancer and a higher need for its treatments such as
US to buy more GSK doses for $651M - report
11:24am, Wednesday, 17'th Nov 2021 Breaking the News 24/7
The United States government has signed a contract for a further 300,000 doses of GlaxoSmithKline''s (GSK) sotrovimab COVID-19 antibody drug, according to a source quoted by the Wall Street Journal
Covid breakthrough as UK''s GlaxoSmithKline strikes $1bn wonder drug deal with US
10:23am, Wednesday, 17'th Nov 2021 Daily Express
A COVID-19 BREAKTHROUGH has been made as UK drugmaker GlaxoSmithKline has signed a huge $1billion deal with US-based Vir Biotechnology.
DNA Vaccines Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the business.
GlaxoSmithKline plc (NYSE:GSK) Raises Dividend to $0.52 Per Share
03:36pm, Tuesday, 16'th Nov 2021 Dakota Financial News
GlaxoSmithKline plc (NYSE:GSK) announced a quarterly dividend on Friday, October 29th, Wall Street Journal reports. Shareholders of record on Friday, November 19th will be paid a dividend of 0.5234 per share by the pharmaceutical company on Thursday, January 13th. This represents a $2.09 dividend on an annualized basis and a dividend yield of 4.85%. The []
Human Rotavirus Vaccine Market Qualitative Insights Key Enhancement & Share Analysis to 2027|Bharat Biotech, Merck, GlaxoSmithKline
01:49pm, Tuesday, 16'th Nov 2021 OpenPR
Rotavirus vaccine is applied to prevent against rotavirus infections which can cause severe diarrhoea amongst young children. Symptoms of rotavirus infection consist of severe diarrhoea, vomiting, fever, and abdominal pain which can cause the disease. Rotavirus vaccine is given by
Sign In
Buy GSK